Zimmer Partners’s Maravai LifeSciences MRVI Stock Holding History

Zimmer Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32,000	Closed	-$1.14M	–	203
2021 Q1	$1.14M	Hold	32,000	–	–	0.02%	139
2020 Q4	$898K	Buy	+32,000	New	+$891K	0.01%	108

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Zimmer Partners's MRVI Position: Q2 2021 in Review

Zimmer Partners sold out of Maravai LifeSciences (MRVI) in Q2 2021, closing a stake of 32,000 shares — an estimated $1.14M sold.

Zimmer Partners first reported a position in MRVI in Q4 2020 and held it in 2 quarters. The position peaked at $1.14M in Q1 2021. 196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

Zimmer Partners reported no remaining Maravai LifeSciences position as of Q2 2021 after selling out during the quarter.
Zimmer Partners sold 32,000 Maravai LifeSciences shares in Q2 2021, an estimated $1.14M.
Zimmer Partners first reported a position in Maravai LifeSciences in Q4 2020 and held it in 2 quarters.
Zimmer Partners's Maravai LifeSciences position peaked at $1.14M in Q1 2021.
196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Zimmer Partners's 13F filing for Q2 2021, filed 16 Aug 2021.